Fig. 4 (abstract P14).
The addition of anti-TIM + anti-CTLA-4 provides no benefit to anti-OX40 + anti-PD-1 combination treatment
Fig. 4 (abstract P14). | Journal for ImmunoTherapy of Cancer
The addition of anti-TIM + anti-CTLA-4 provides no benefit to anti-OX40 + anti-PD-1 combination treatment